Physician profile
Justin Jay Stenquist
NPI 1285096503
$7,313.69
in general payments reported to CMS, 2019-2025
49 companies · $1,713 in 2025
The $1,713 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.60 · 2020: $51.73 · 2021: $525 · 2022: $1,463 · 2023: $1,740 · 2024: $1,785 · 2025: $1,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,238.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,160.37 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $530.31 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $489.97 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $467.92 | 2021-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $465.20 | 2021-2025 | |
| Abbott Laboratories | $439.77 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Prodigy |
| Pfizer INC. | $437.28 | 2023-2025 | |
| Lilly USA, LLC | $423.09 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $358.56 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.36 | 2019-2024 | Jardiance |
| Exact Sciences Corporation | $160.20 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $156.71 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $140.22 | 2021-2025 | Belsomra, Gardasil 9, Steglatro |
| Biohaven Pharmaceutical Holding Company LTD. | $136.29 | 2022 | |
| Sanofi-Aventis U.S. LLC | $129.03 | 2022-2024 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Stenquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.